Floatz logo

65 assets in Rectal Cancer

Therapeutic assets addressing Rectal Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Ropidoxuridine
Rectal Cancer
National Cancer Institute (NCI)P1CC (41)
Vactosertib
Rectal Cancer
David WaldP1CC (41)
Copper Cu 64 Anti-Cea Monoclonal Antibody M5A
Rectal Cancer
City of Hope Medical CenterEarly P1C (39)
[18f]f-resca-g5
Rectal Cancer
RenJi HospitalN/AD (30)
[18f]f-resca-rb14
Rectal Cancer
RenJi HospitalN/AD (30)
[18F]F-RESCA-RND20
Rectal Cancer
RenJi HospitalN/AD (30)
[18F]F-RESCA-T4
Rectal Cancer
RenJi HospitalN/AD (30)
[18f]f-resca-wwh347
Rectal Cancer
RenJi HospitalN/AD (30)
[68Ga]Ga-DOTA-H2D3
Rectal Cancer
RenJi HospitalN/AD (30)
[68ga]ga-nota-g5
Rectal Cancer
RenJi HospitalN/AD (30)
[68ga]ga-nota-rnd20
Rectal Cancer
RenJi HospitalN/AD (30)
[68ga]ga-nota-t4
Rectal Cancer
RenJi HospitalN/AD (30)
[68Ga]Ga-NOTA-WWH347
Rectal Cancer
RenJi HospitalN/AD (30)
Envafolimab
Rectal Cancer
Yunnan Cancer HospitalP2NR ()
Folic Acid
Rectal Cancer
Lithuanian University of Health SciencesP2NR ()
Showing 51 to 65 of 65 assets
PreviousPage 2 of 2Next